Refining the definition of hypereosinophilic syndrome

Hans Uwe Simon; Marc E. Rothenberg; Bruce S. Bochner; Peter F. Weller; Andrew J. Wardlaw; Michael E. Wechsler; Lanny J. Rosenwasser; Florence Roufosse; Gerald J. Gleich; Amy D. Klion

doi:10.1016/j.jaci.2010.03.042

Refining the definition of hypereosinophilic syndrome

Hans Uwe Simon^*, Marc E. Rothenberg, Bruce S. Bochner, Peter F. Weller, Andrew J. Wardlaw, Michael E. Wechsler, Lanny J. Rosenwasser, Florence Roufosse, Gerald J. Gleich, Amy D. Klion

^*Corresponding author for this work

Medicine, Allergy Division

Research output: Contribution to journal › Article › peer-review

251 Scopus citations

Abstract

Because of advances in our understanding of the hypereosinophilic syndrome (HES) and the availability of novel therapeutic agents, the original criteria defining these disorders are becoming increasingly problematic. Here, we discuss shortcomings with the current definition of HES and recent developments in the classification of these disorders. Despite significant progress in our understanding of the pathogenesis of some forms of HES, the current state of knowledge is still insufficient to formulate a new comprehensive etiologic definition of HESs. Nevertheless, we suggest a new working definition that overcomes some of the most obvious limitations with the original definition.

Original language	English (US)
Pages (from-to)	45-49
Number of pages	5
Journal	Journal of Allergy and Clinical Immunology
Volume	126
Issue number	1
DOIs	https://doi.org/10.1016/j.jaci.2010.03.042
State	Published - Jul 2010

Funding

Disclosure of potential conflict of interest: H.-U. Simon has received research support from GlaxoSmithKline, AstraZeneca, Roche, CSL Behring, and Nycomed , and has provided legal consultation or expert witness testimony for Pfizer on the topic of general pharmacology. M. E. Rothenberg has consulted for and given talks for Merck; has consulted for Centocor, Ception Therapeutics, Nycomed, Array BioPharma, Biocrystal Pharmaceuticals, and Endo Pharmaceuticals; has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Dana Foundation ; is on the medical advisory board of the American Partnership for Eosinophilic Diseases; and is on the executive council of the International Eosinophil Society. B. S. Bochner has consulted for Sanofi-Aventis and GlaxoSmithKline and has received research support from Sanofi-Aventis . P. F. Weller has received research support from Merck and has provided legal consultation services or expert witness testimony on the topic of eosinophilic diseases. A. J. Wardlaw is on advisory boards for GlaxoSmithKline and has received research support from GlaxoSmithKline, Pfizer, and AstraZeneca . M. E. Wechsler has consulted for and given talks for Genentech, Merck, and Novartis; has consulted for MedImmune, Medicinova, and GlaxoSmithKline; is on the data safety monitoring board for MAP Pharmaceuticals; and has received research support from the National Institutes of Health and GlaxoSmithKline . L. J. Rosenwasser has received research support from Novartis and Genentech and has consulted for Alcon, Sanofi-Aventis, GlaxoSmithKline, and AstraZeneca. F. Roufosse has consulted for GlaxoSmithKline. G. J. Gleich has provided legal consultation or expert witness testimony on the topic of heparin contamination and is on the board of directors for the American Partnership for Eosinophilic Disorders. A. D. Klion declares that she has no relevant conflicts of interest to disclose.

Keywords

Definition
eosinophilia
eosinophilic leukemia
hypereosinophilic syndromes

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2010.03.042

Cite this

@article{acf846bfad2c4e8f98acf4a46e645091,

title = "Refining the definition of hypereosinophilic syndrome",

abstract = "Because of advances in our understanding of the hypereosinophilic syndrome (HES) and the availability of novel therapeutic agents, the original criteria defining these disorders are becoming increasingly problematic. Here, we discuss shortcomings with the current definition of HES and recent developments in the classification of these disorders. Despite significant progress in our understanding of the pathogenesis of some forms of HES, the current state of knowledge is still insufficient to formulate a new comprehensive etiologic definition of HESs. Nevertheless, we suggest a new working definition that overcomes some of the most obvious limitations with the original definition.",

keywords = "Definition, eosinophilia, eosinophilic leukemia, hypereosinophilic syndromes",

author = "Simon, {Hans Uwe} and Rothenberg, {Marc E.} and Bochner, {Bruce S.} and Weller, {Peter F.} and Wardlaw, {Andrew J.} and Wechsler, {Michael E.} and Rosenwasser, {Lanny J.} and Florence Roufosse and Gleich, {Gerald J.} and Klion, {Amy D.}",

note = "Funding Information: Disclosure of potential conflict of interest: H.-U. Simon has received research support from GlaxoSmithKline, AstraZeneca, Roche, CSL Behring, and Nycomed , and has provided legal consultation or expert witness testimony for Pfizer on the topic of general pharmacology. M. E. Rothenberg has consulted for and given talks for Merck; has consulted for Centocor, Ception Therapeutics, Nycomed, Array BioPharma, Biocrystal Pharmaceuticals, and Endo Pharmaceuticals; has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Dana Foundation ; is on the medical advisory board of the American Partnership for Eosinophilic Diseases; and is on the executive council of the International Eosinophil Society. B. S. Bochner has consulted for Sanofi-Aventis and GlaxoSmithKline and has received research support from Sanofi-Aventis . P. F. Weller has received research support from Merck and has provided legal consultation services or expert witness testimony on the topic of eosinophilic diseases. A. J. Wardlaw is on advisory boards for GlaxoSmithKline and has received research support from GlaxoSmithKline, Pfizer, and AstraZeneca . M. E. Wechsler has consulted for and given talks for Genentech, Merck, and Novartis; has consulted for MedImmune, Medicinova, and GlaxoSmithKline; is on the data safety monitoring board for MAP Pharmaceuticals; and has received research support from the National Institutes of Health and GlaxoSmithKline . L. J. Rosenwasser has received research support from Novartis and Genentech and has consulted for Alcon, Sanofi-Aventis, GlaxoSmithKline, and AstraZeneca. F. Roufosse has consulted for GlaxoSmithKline. G. J. Gleich has provided legal consultation or expert witness testimony on the topic of heparin contamination and is on the board of directors for the American Partnership for Eosinophilic Disorders. A. D. Klion declares that she has no relevant conflicts of interest to disclose. ",

year = "2010",

month = jul,

doi = "10.1016/j.jaci.2010.03.042",

language = "English (US)",

volume = "126",

pages = "45--49",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Refining the definition of hypereosinophilic syndrome

AU - Simon, Hans Uwe

AU - Rothenberg, Marc E.

AU - Bochner, Bruce S.

AU - Weller, Peter F.

AU - Wardlaw, Andrew J.

AU - Wechsler, Michael E.

AU - Rosenwasser, Lanny J.

AU - Roufosse, Florence

AU - Gleich, Gerald J.

AU - Klion, Amy D.

N1 - Funding Information: Disclosure of potential conflict of interest: H.-U. Simon has received research support from GlaxoSmithKline, AstraZeneca, Roche, CSL Behring, and Nycomed , and has provided legal consultation or expert witness testimony for Pfizer on the topic of general pharmacology. M. E. Rothenberg has consulted for and given talks for Merck; has consulted for Centocor, Ception Therapeutics, Nycomed, Array BioPharma, Biocrystal Pharmaceuticals, and Endo Pharmaceuticals; has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Dana Foundation ; is on the medical advisory board of the American Partnership for Eosinophilic Diseases; and is on the executive council of the International Eosinophil Society. B. S. Bochner has consulted for Sanofi-Aventis and GlaxoSmithKline and has received research support from Sanofi-Aventis . P. F. Weller has received research support from Merck and has provided legal consultation services or expert witness testimony on the topic of eosinophilic diseases. A. J. Wardlaw is on advisory boards for GlaxoSmithKline and has received research support from GlaxoSmithKline, Pfizer, and AstraZeneca . M. E. Wechsler has consulted for and given talks for Genentech, Merck, and Novartis; has consulted for MedImmune, Medicinova, and GlaxoSmithKline; is on the data safety monitoring board for MAP Pharmaceuticals; and has received research support from the National Institutes of Health and GlaxoSmithKline . L. J. Rosenwasser has received research support from Novartis and Genentech and has consulted for Alcon, Sanofi-Aventis, GlaxoSmithKline, and AstraZeneca. F. Roufosse has consulted for GlaxoSmithKline. G. J. Gleich has provided legal consultation or expert witness testimony on the topic of heparin contamination and is on the board of directors for the American Partnership for Eosinophilic Disorders. A. D. Klion declares that she has no relevant conflicts of interest to disclose.

PY - 2010/7

Y1 - 2010/7

N2 - Because of advances in our understanding of the hypereosinophilic syndrome (HES) and the availability of novel therapeutic agents, the original criteria defining these disorders are becoming increasingly problematic. Here, we discuss shortcomings with the current definition of HES and recent developments in the classification of these disorders. Despite significant progress in our understanding of the pathogenesis of some forms of HES, the current state of knowledge is still insufficient to formulate a new comprehensive etiologic definition of HESs. Nevertheless, we suggest a new working definition that overcomes some of the most obvious limitations with the original definition.

AB - Because of advances in our understanding of the hypereosinophilic syndrome (HES) and the availability of novel therapeutic agents, the original criteria defining these disorders are becoming increasingly problematic. Here, we discuss shortcomings with the current definition of HES and recent developments in the classification of these disorders. Despite significant progress in our understanding of the pathogenesis of some forms of HES, the current state of knowledge is still insufficient to formulate a new comprehensive etiologic definition of HESs. Nevertheless, we suggest a new working definition that overcomes some of the most obvious limitations with the original definition.

KW - Definition

KW - eosinophilia

KW - eosinophilic leukemia

KW - hypereosinophilic syndromes

UR - http://www.scopus.com/inward/record.url?scp=77954089699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954089699&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2010.03.042

DO - 10.1016/j.jaci.2010.03.042

M3 - Article

C2 - 20639008

AN - SCOPUS:77954089699

SN - 0091-6749

VL - 126

SP - 45

EP - 49

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 1

ER -

Refining the definition of hypereosinophilic syndrome

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this